NeuroPace (NASDAQ:NPCE) Posts Earnings Results

NeuroPace (NASDAQ:NPCE) released its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07, Zacks reports. The business had revenue of $21.47 million for the quarter, compared to the consensus estimate of $21.14 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.

NeuroPace Trading Down 2.4 %

NASDAQ:NPCE opened at $11.63 on Thursday. NeuroPace has a 12-month low of $5.45 and a 12-month high of $15.77. The firm has a market cap of $347.13 million, a PE ratio of -11.63 and a beta of 2.05. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The stock has a fifty day moving average price of $12.72 and a 200 day moving average price of $9.76.

Insiders Place Their Bets

In other NeuroPace news, major shareholder Ltd. Kck sold 5,270,845 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total transaction of $49,545,943.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Martha Morrell sold 78,334 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the completion of the sale, the insider now directly owns 81,993 shares in the company, valued at approximately $1,124,943.96. This represents a 48.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,352,479 shares of company stock worth $50,670,217 in the last quarter. 22.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

NPCE has been the topic of a number of research analyst reports. UBS Group began coverage on NeuroPace in a research report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 target price on the stock. Cantor Fitzgerald boosted their price objective on NeuroPace from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday. JPMorgan Chase & Co. increased their target price on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Finally, Wells Fargo & Company lifted their target price on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, January 30th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $15.20.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.